Galapagos NV (Ticker: GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, dedicated to discovering and developing innovative small molecule therapeutics aimed at addressing severe diseases with significant unmet medical needs. The company boasts a promising and diverse pipeline, particularly in the areas of immunology and inflammation, underpinned by its proprietary drug discovery platform. Galapagos strategically collaborates with major pharmaceutical partners to bolster its research capabilities, thereby enhancing its competitive position within the biotechnology sector and driving forward its mission to tackle pressing health challenges. Show more

Location: GENERAAL DE WITTELAAN L11 A3, MECHELEN, BELGIUM, 2800, Mechelen, 2800, USA | Website: https://www.glpg.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

2.20B

52 Wk Range

$22.36 - $37.78

Previous Close

$33.38

Open

$33.38

Volume

71,192

Day Range

$33.17 - $33.60

Enterprise Value

-1.332B

Cash

75.74M

Avg Qtr Burn

-62.61M

Insider Ownership

25.35%

Institutional Own.

23.24%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Jyseleca (Filgotinib) Details Ulcerative colitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Filgotinib Details Crohns disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Filgotinib Details Axial spondyloarthritis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG3667 Details Dermatomyositis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG3667 Details Systemic lupus erythematosus	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5101 (CD19 CAR-T) Details Relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5301 BCMA CAR-T Details Multiple myeloma, High Refractory Multiple Myeloma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5201 (CD19 CAR-T) Details Small lymphocytic lymphoma , Chronic lymphocytic leukemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG5101 (CD19 CAR-T) Details Systemic lupus erythematosus, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG3970 (SIK2/3 inhibitor) Details Psoriasis, Rheumatoid arthritis, Ulcerative colitis, Systemic lupus erythematosus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ziritaxestat (GLPG1690) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG1205 (GPR84 inhibitor) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG4716 (CHIT1/AMCase inhibitor) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GLPG2737 (CFTR inhibitor) Details Autosomal Dominant Polycystic Kidney Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.